Q-omics provides the consensus-scored H2BP5 profile across patient tissues and cancer cell-line models. H2BP5 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, H2BP5 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, H2BP5 RNA expression shows 10,814 significant gene co-expression associations, with the highest sampling consensus in LUSC. Together, these results highlight BRCA, KIRC, and LUSC as cancer lineages where H2BP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2BP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2BP5 survival associations across molecular data types. H2BP5 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2BP5 RNA expression–survival associations across cancer types. High H2BP5 expression shows unfavorable associations in BRCA, STAD, HNSC, KIRP and UCEC, but favorable associations in ESCA. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for H2BP5 RNA expression.
This table summarizes H2BP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for H2BP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2BP5 shows higher tumor expression in KIRC. The KIRC box plot shows higher H2BP5 RNA expression in tumor versus normal tissue (log2 FC = +0.021, t-test p = .031).
This table shows molecular features associated with H2BP5 in patient tissues and cancer cell lines. In patient samples, H2BP5 shows the broadest associations at the RNA and protein expression levels, with LUSC recurring as the lineage with the largest associated feature set.
